Advice

Following a full submission.

Rituximab is accepted for use within NHS Scotland for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with cyclophosphamide, vincristine and prednisolone (CVP) chemotherapy.

Rituximab is for use only by oncologists or haematologists who have expertise in treating lymphoma. It should be administered in a hospital environment where full resuscitation facilities are available. Limited results show that rituximab plus CVP significantly increased the time to treatment failure compared with CVP alone.

Download detailed advice26KB (PDF)

Download

Medicine details

Medicine name:
Rituximab (MabThera®)
SMC ID:
135/04
Indication:
Follicular lymphoma in combination with CVP chemotherapy
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published
13 December 2004